155 related articles for article (PubMed ID: 34581841)
1. Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study.
Tsutsumi T; Imai S; Kashiwagi H; Sato Y; Sugawara M; Takekuma Y
Eur J Clin Pharmacol; 2022 Feb; 78(2):279-286. PubMed ID: 34581841
[TBL] [Abstract][Full Text] [Related]
2. [Verification of Relationship between Administration of Linezolid and Vomiting].
Tsutsumi T; Imai S; Yamada K; Yamada T; Kasashi K; Kobayashi M; Iseki K
Yakugaku Zasshi; 2019; 139(7):1055-1061. PubMed ID: 31257252
[TBL] [Abstract][Full Text] [Related]
3. A retrospective test for a possible relationship between linezolid-induced thrombocytopenia and hyponatraemia.
Tanaka R; Suzuki Y; Morinaga Y; Iwao M; Takumi Y; Hashinaga K; Tatsuta R; Hiramatsu K; Kadota JI; Itoh H
J Clin Pharm Ther; 2021 Apr; 46(2):343-351. PubMed ID: 33016566
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case-control studies of incidence and associated risk factors.
Mori N; Kamimura Y; Kimura Y; Hirose S; Aoki Y; Bito S
Eur J Clin Pharmacol; 2018 Apr; 74(4):405-411. PubMed ID: 29222713
[TBL] [Abstract][Full Text] [Related]
5. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.
Ichie T; Suzuki D; Yasui K; Takahashi H; Matsuda M; Hayashi H; Sugiura Y; Sugiyama T
J Clin Pharm Ther; 2015 Jun; 40(3):279-84. PubMed ID: 25732525
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients.
Dai Y; Jiang S; Chen X; Han L; Zhang C; Yu X; Zhang X
J Clin Pharm Ther; 2021 Jun; 46(3):807-813. PubMed ID: 33555057
[TBL] [Abstract][Full Text] [Related]
7. Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days.
Sato Y; Iguchi M; Kato Y; Morioka H; Hirabayashi A; Tetsuka N; Tomita Y; Kato D; Yamada K; Kimura H; Yagi T
Nagoya J Med Sci; 2020 Aug; 82(3):407-414. PubMed ID: 33132425
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study.
Tsutsumi T; Imai S; Momo K; Kashiwagi H; Sato Y; Sugawara M; Takekuma Y
Int J Clin Pharm; 2024 Apr; 46(2):421-428. PubMed ID: 38158470
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Incidence of Hyponatremia between Linezolid and Vancomycin by Propensity Score Matching Analysis.
Tanaka R; Morinaga Y; Iwao M; Tatsuta R; Hashimoto T; Hiramatsu K; Itoh H
Biol Pharm Bull; 2023; 46(10):1365-1370. PubMed ID: 37779038
[TBL] [Abstract][Full Text] [Related]
10. Linezolid and the risk of lactic acidosis: Data mining and analysis of the FDA Adverse Event Reporting System.
Dai Y; Wang Y; Zeng Y; Zhang C; Zhou Z; Shi D
J Clin Pharm Ther; 2020 Dec; 45(6):1422-1426. PubMed ID: 32776380
[TBL] [Abstract][Full Text] [Related]
11. [Risk factors for development of hematotoxicity in elderly patients treated with Linezolid].
Bo SY; Su AM; Yang F; Yang L
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jun; 45(6):533-538. PubMed ID: 35658376
[No Abstract] [Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia.
Onita T; Ishihara N; Ikebuchi A; Yano T; Nishimura N; Tamaki H; Ikawa K; Morikawa N; Naora K
J Clin Pharm Ther; 2022 Dec; 47(12):2041-2048. PubMed ID: 35893441
[TBL] [Abstract][Full Text] [Related]
13. Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study.
Thi Phuong Thao L; Duc Trung N; Thi My L; Minh Hong L; Viet Hoan B; Quang Hung V; Dang Hai P
J Infect Dev Ctries; 2024 Feb; 18(2):285-290. PubMed ID: 38484357
[TBL] [Abstract][Full Text] [Related]
14. A risk factor-based predictive model for linezolid-induced anaemia: A 7-year retrospective study.
Qin Y; Liu Y; Chen Z; Cao M; Shen Y; Ye Y
J Clin Pharm Ther; 2021 Dec; 46(6):1591-1599. PubMed ID: 34287998
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Analysis of Risk Factors for Linezolid-Associated Hyponatremia in Japanese Patients.
Tanaka R; Suzuki Y; Takumi Y; Iwao M; Sato Y; Hashinaga K; Hiramatsu K; Kadota JI; Itoh H
Biol Pharm Bull; 2016; 39(12):1968-1973. PubMed ID: 27904038
[TBL] [Abstract][Full Text] [Related]
16. Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: a retrospective study.
Cui D; Hu X; Shi L; Wang D; Chen G
J Chemother; 2023 Sep; 35(5):404-410. PubMed ID: 36322121
[TBL] [Abstract][Full Text] [Related]
17. Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia.
Britt NS; Potter EM; Patel N; Steed ME
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264856
[TBL] [Abstract][Full Text] [Related]
18. Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case-control study.
Chen C; Li Y; Yu J; Qian S
Clin Transl Oncol; 2022 Mar; 24(3):540-545. PubMed ID: 34716540
[TBL] [Abstract][Full Text] [Related]
19. Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy.
Nedved AN; DeFrates SR; Hladnik LM; Stockerl-Goldstein KE
Pharmacotherapy; 2016 Oct; 36(10):1087-1094. PubMed ID: 27521990
[TBL] [Abstract][Full Text] [Related]
20. Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia.
Inoue Y; Takekuma Y; Miyai T; Kashiwagi H; Sato Y; Sugawara M; Imai S
Eur J Clin Pharmacol; 2023 Mar; 79(3):415-425. PubMed ID: 36715711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
